Biocon commercial rights on biosimilar adalimumab extends to global markets Farhat Nasim8 May 2019 9:45 AM ISTBiocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing...